

**REMARKS:**

Claims 1, 2 and 15-21 are in the case and presented for consideration.

To address the Examiner's objections to the claims, claim 2 has been amended to add the word "or" between the second and second from last compound and claims have been submitted to replace former claims 4-6 and 10-14 in a form which is believed proper under U.S. patent practice.

To address the Examiner's rejection of claims 1-14 under 35 U.S.C. 112, second paragraph, additional corrections have been made which will be enumerated below.

Claims 1-7 and 10-14 have also been rejected as fully anticipated by the Bressi et al. reference.


Bressi et al., J. Med. Chem. 2000, 43, 4135 teaches certain adenosine derivatives possessing an activity against *Trypanosoma brucei*. The claims have accordingly been amended to exclude parasitoses from the list of disease states in the claims concerning the medical uses of the adenosine derivatives. We did not find any mention of a composition containing the adenosine derivatives in this document.

In claim 1, the wording "2-6 carbon atoms" has been corrected to read -- 2nd to 6th carbon atom -- and "hydrogen" has been deleted from the definition of R1. The parenthetical phrases starting with "e.g." were also deleted.

Also removed are the lines drawn in the 1', 2' and 3' position in the formula (I).

By this amendment, thus, the application and claim are believed to be in condition for allowance and favorable action is respectfully requested.

Respectfully submitted,



Peter C. Michalos  
Reg. No. 28,643  
Attorney for Applicants  
(845) 359-7700

Dated: June 19, 2007

**NOTARO & MICHALOS P.C.**  
100 Dutch Hill Road, Suite 110  
Orangeburg, New York 10962-2100

**Customer No. 21706**

M:\PAT-AMD\J507-005\J507-005US.Amendment.wpd